查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088688

敗血症診斷市場：依產品類型、技術、最終用戶和通路分類－2026-2032年全球市場預測

Sepsis Diagnostic Market by Product Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，敗血症診斷市場將成長至 17,4459 億美元，複合年成長率為 8.35%。

主要市場統計數據
基準年 2025 9.9488億美元
預計年份：2026年 1,075,170,000 美元
預測年份 2032 1,744,590,000 美元
複合年成長率 (%) 8.35%

膿毒症診斷市場簡介

由於敗血症的診斷仍然是急診護理中最耗時且致死率最高的疾病之一，因此它正成為醫院、實驗室和醫療保健系統的核心優先事項。根據世界衛生組織 (WHO) 估計，2017 年全球約有 4,900 萬人被診斷出罹患敗血症，約有 1,100 萬人死於敗血症，約佔全球所有死亡人數的五分之一。在美國，疾病管制與預防中心 (CDC) 的報告顯示，每年至少有 170 萬成年人患有敗血症，其中約 35 萬人死於醫院或轉入臨終關懷機構後。

敗血症診斷的變革性變化

敗血症的診斷模式正從依賴培養的工作流程轉向整合式、時效性強的診斷路徑。雖然傳統的血液培養對於病原體檢測和抗生素敏感性試驗仍然至關重要，但獲得結果所需的時間可能會延誤標靶治療的啟動。快速分子診斷、基質輔助雷射脫附游離飛行質譜（MALDI-TOF）、宿主免疫反應特徵以及自動化檢測平台正被擴大用於縮短從懷疑到獲得有效結果的時間。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善風險預測、工作流程優先排序和臨床決策支持，對敗血症診斷產生了累積的影響。 AI 模型分析電子健康記錄資料、生命徵象、實驗室趨勢、用藥史、合併症和微生物訊號，能夠比單純人工審核更早發現病情惡化。其最有效的應用並非作為取代臨床醫生的獨立工具，而是作為整合到檢驗的膿毒症診療方案中的支持系統。

關鍵區域洞察：膿毒症診斷技術的應用

由於醫院容量不斷擴大、患者群體龐大，以及中國、印度、日本、韓國和澳洲等國自動化微生物和分子檢測技術的日益普及，亞太地區已成為敗血症診斷技術應用的關鍵區域。該地區的感染疾病負擔、不斷擴大的重症監護基礎設施以及對抗生素抗藥性的日益關注，都推動了對快速病原體鑑定和基於生物標記的風險評估的需求。北美仍然是成熟的創新中心，這得益於醫院品質的提升、美國疾病管制與預防食品藥物管理局）的敗血症宣傳計畫、美國食品藥物管理局（FDA）監管的診斷流程，以及急診室、重症監護室和中心檢查室積極採用快速病原體鑑定技術。

該集團在主要經濟區的主要見解

在東協市場，敗血症診斷正透過對醫院檢查室、感染疾病監測和重症監護能力的投資而不斷進步，但都市區轉診醫療機構之間仍然存在就醫難的問題。在海灣合作理事會（GCC）國家，診斷技術的應用正透過先進的醫院系統、數位健康計畫和重症檢查室網路加速發展，尤其是在敗血症管理已融入急診和重症監護治療流程的地區。這些區域趨勢凸顯了擴充性、高度互通性的診斷技術的重要性，這些技術能夠適應不同檢查室的成熟度差異。

主要國家膿毒症診斷趨勢

由於敗血症負擔沉重、醫院品質指標高、抗生素使用要求嚴格，以及對快速分子檢測和人工智慧驅動的臨床決策支援的強烈需求，美國在敗血症診斷創新技術的應用方面處於領先地位。在加拿大，標準化診療路徑、檢查室品質以及各省醫療保健系統間的公平取得是重點。同時，墨西哥和巴西在重症監護需求不斷成長和三級醫療基礎設施投資的推動下，正在擴大醫院診斷規模。在英國、德國、法國、義大利和西班牙，對符合抗生素使用規範的診斷方法的需求旺盛，其中德國和法國擁有先進的檢查室基礎設施，而英國則注重在所有急診場所推廣規範化的膿毒症診療流程。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠縮短獲得有效結果時間的臨床檢驗方案，而不是簡單地增加檢測數量。最有效的策略是將最佳化的血液培養、快速分子診斷、生物標記檢測、抗生素敏感性檢測流程以及人工智慧輔助的分診相結合，並將其整合到一個可靠且可操作的膿毒症診療路徑中，供急診醫生、重症監護醫生、感染疾病專家和實驗室團隊使用。解決方案的設計應與現有的實驗室資訊系統、電子健康記錄和抗生素使用方案整合。

調查方法

本執行摘要採用系統性的二手調查方法編寫，所檢驗資訊來源。主要資訊來源包括世界衛生組織和美國疾病管制與預防中心關於膿毒症負擔的數據、關於膿毒症生物標記和分子診斷的同行評審文獻、關於抗菌素抗藥性的政策文件、關於體外診斷醫療設備和醫療設備軟體的監管指南，以及公開的醫院品質舉措。

結論

敗血症診斷正朝著更一體化的時代發展，其特點是速度快、準確性高、應用合理，並與臨床工作流程整合。雖然血液培養仍然是一項基礎檢測，但分子診斷、宿主反應生物標記、自動化微生物檢測、乳酸和抑鈣素原檢測、抗生素敏感性檢測流程以及人工智慧驅動的決策支援等技術正日益影響著這一領域，以幫助早期識別高風險患者。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：敗血症診斷市場：依產品類型分類

  • 裝置
    • 分析器
    • 即時檢測設備
  • 試劑和試劑盒
    • 生物標記試劑盒
    • 培養基
  • 軟體服務
    • 諮詢服務
    • 資料管理軟體

第8章：敗血症診斷市場：依技術分類

  • ELISA
    • 競爭性ELISA
    • 夾心ELISA
  • 流式細胞技術
    • 常規流式細胞技術
    • 成像流式細胞技術
  • NGS
    • 標靶定序
    • 全基因測序
  • PCR
    • 多重PCR
    • 即時PCR

第9章：膿毒症診斷市場：依最終用戶分類

  • 門診醫療機構
    • 診所
    • 門診中心
  • 診斷檢查室
    • 臨床實驗室
    • 參考實驗室
  • 醫院
    • 綜合醫院
    • 三級醫療機構

第10章 膿毒症診斷市場：依分銷管道分類

  • 直接的
  • 間接
    • 經銷商
    • 電子商務

第11章 敗血症診斷市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：敗血症診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 敗血症診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Alifax Srl
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Boditech Med Inc.
  • Bruker Corporation
  • CytoSorbents Corporation
  • DiaSorin SpA
  • EKF Diagnostics
  • F. Hoffmann-La Roche AG
  • Immunexpress Inc.
  • Koninklijke Philips NV
  • McKesson Corporation
  • Merck KGaA
  • Molzym GmbH & Co. KG
  • Nanomix Inc.
  • Oracle Corporation
  • QIAGEN NV
  • Response Biomedical Corporation
  • Seegene Inc.
  • Siemens Healthineers
  • T2 Biosystems
  • Thermo Fisher Scientific, Inc.
  • Wolters Kluwer NV
Product Code: MRR-A339DAEFABA1

The Sepsis Diagnostic Market is projected to grow by USD 1,744.59 million at a CAGR of 8.35% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 994.88 million
Estimated Year [2026] USD 1,075.17 million
Forecast Year [2032] USD 1,744.59 million
CAGR (%) 8.35%

Sepsis Diagnostic Market Introduction

Sepsis diagnostics are becoming a core priority for hospitals, laboratories, and health systems because sepsis remains one of the most time-sensitive and high-mortality conditions in acute care. The World Health Organization estimates that sepsis affected approximately 49 million people and was associated with about 11 million deaths worldwide in 2017, representing nearly one-fifth of global deaths. In the United States, the CDC reports that at least 1.7 million adults develop sepsis annually, with roughly 350,000 deaths during hospitalization or discharge to hospice.

The sepsis diagnostic landscape spans blood culture, lactate testing, procalcitonin, C-reactive protein, host-response assays, molecular diagnostics, multiplex syndromic panels, antimicrobial susceptibility testing, and clinical decision support tools. Demand is rising as emergency departments, intensive care units, and microbiology laboratories seek faster pathogen identification, earlier risk stratification, and more precise antimicrobial stewardship. This makes accurate, rapid, and workflow-ready sepsis testing essential for improving treatment decisions and reducing avoidable delays.

Transformative Shifts in Sepsis Diagnostics

The sepsis diagnostic landscape is shifting from culture-dependent workflows toward integrated, time-sensitive diagnostic pathways. Conventional blood culture remains essential for pathogen recovery and antimicrobial susceptibility testing, but its turnaround time can delay targeted therapy. Rapid molecular diagnostics, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, host immune-response signatures, and automated laboratory platforms are increasingly used to shorten the interval from suspicion to actionable results.

A second transformation is occurring at the care-delivery level. Sepsis screening is moving beyond the ICU into emergency departments, medical wards, ambulatory escalation pathways, and remote triage programs. Hospitals are prioritizing diagnostic solutions that combine clinical scoring, laboratory biomarkers, electronic health record alerts, and stewardship protocols to reduce inappropriate antibiotic use while supporting early intervention for high-risk patients. The shift is also reinforcing the need for interoperability between laboratory information systems, electronic health records, and point-of-care workflows.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact on sepsis diagnostics by improving risk prediction, workflow prioritization, and clinical decision support. AI-enabled models can analyze electronic health record data, vital signs, laboratory trends, medication history, comorbidities, and microbiology signals to flag deterioration earlier than manual review alone. The strongest applications are not stand-alone replacements for clinicians but assistive systems embedded into validated sepsis protocols.

The opportunity is tied to governance and evidence. Hospitals are demanding transparent model performance, bias monitoring, local validation, human oversight, and integration with laboratory information systems. AI can also support diagnostic stewardship by helping clinicians decide when to order blood cultures, lactate, procalcitonin, molecular panels, or repeat testing, thereby aligning rapid sepsis diagnostics with cost control and antimicrobial stewardship. As regulatory expectations for clinical software mature, explainability, auditability, and real-world monitoring are becoming essential adoption criteria.

Key Regional Insights: Sepsis Diagnostic Adoption

Asia-Pacific is a major sepsis diagnostic adoption region due to expanding hospital capacity, large patient populations, and rising use of automated microbiology and molecular testing in China, India, Japan, South Korea, and Australia. The region's infectious disease burden, growing intensive care infrastructure, and increasing focus on antimicrobial resistance are strengthening demand for rapid pathogen identification and biomarker-based risk assessment. North America remains a mature innovation hub, supported by hospital quality initiatives, CDC sepsis awareness programs, FDA-regulated diagnostic pathways, and strong adoption of rapid pathogen identification technologies across emergency departments, ICUs, and centralized laboratories.

Europe benefits from coordinated antimicrobial resistance strategies, advanced laboratory networks, and strong demand for evidence-based diagnostic stewardship under rigorous in vitro diagnostic and clinical performance expectations. Latin America is expanding access to blood culture automation and critical care diagnostics, with Brazil and Mexico serving as important adoption centers as tertiary hospitals modernize microbiology capabilities. The Middle East is investing in tertiary care infrastructure, digital health, and laboratory modernization, particularly in urban hospital networks, while Africa faces the highest need for scalable, affordable sepsis diagnostics that can operate across resource-variable settings where timely blood culture access, trained personnel, and laboratory connectivity remain uneven.

Key Group Insights Across Strategic Economies

ASEAN markets are advancing sepsis diagnostics through investment in hospital laboratories, infectious disease surveillance, and critical care capacity, although access remains uneven between urban referral centers and rural facilities. The GCC is accelerating uptake through premium hospital systems, digital health programs, and centralized laboratory networks, particularly where sepsis management is integrated into emergency and intensive care pathways. These group-level dynamics highlight the importance of diagnostics that are scalable, interoperable, and adaptable to different levels of laboratory maturity.

The European Union is shaped by regulatory rigor, antimicrobial resistance policy, cross-border health technology assessment, and growing emphasis on diagnostic stewardship within hospital infection management. BRICS countries represent a major clinical-volume opportunity because China, India, Brazil, Russia, and South Africa combine large patient pools with growing demand for cost-effective rapid diagnostics and more resilient laboratory systems. G7 markets lead in clinical validation, reimbursement sophistication, quality-based care pathways, and AI-enabled decision support, while NATO member countries increasingly emphasize resilient diagnostics, infectious disease preparedness, supply chain continuity, and hospital readiness for emerging biological threats.

Key Country Insights in Sepsis Diagnostics

The United States leads adoption of sepsis diagnostic innovation due to high sepsis burden, hospital quality metrics, antimicrobial stewardship requirements, and strong demand for rapid molecular testing and AI clinical decision support. Canada emphasizes standardized care pathways, laboratory quality, and equitable access across provincial health systems, while Mexico and Brazil are expanding hospital-based diagnostics amid rising critical care needs and investment in tertiary care infrastructure. The United Kingdom, Germany, France, Italy, and Spain demonstrate strong demand for antimicrobial stewardship-aligned diagnostics, with Germany and France supported by advanced laboratory infrastructure and the United Kingdom emphasizing protocolized sepsis recognition across acute care settings.

Russia maintains demand for hospital microbiology modernization and broader access to timely pathogen identification, while China and India are among the most important sepsis diagnostic adoption markets due to scale, infectious disease burden, expanding tertiary care, and growing laboratory automation. Japan, Australia, and South Korea show strong adoption potential for automated platforms, rapid pathogen identification, host-response testing, and digital sepsis surveillance, supported by sophisticated hospital systems, robust diagnostic quality standards, and aging populations that elevate sepsis risk. Across these countries, adoption is increasingly influenced by evidence of clinical utility, workflow integration, and the ability to support targeted antimicrobial therapy.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that reduce time to actionable results rather than simply adding test volume. The strongest strategies combine blood culture optimization, rapid molecular diagnostics, biomarker testing, antimicrobial susceptibility workflows, and AI-enabled triage into practical sepsis pathways that emergency physicians, intensivists, infectious disease specialists, and laboratory teams can trust. Solutions should be designed for integration with existing laboratory information systems, electronic health records, and antimicrobial stewardship programs.

Commercial success will depend on demonstrating measurable value: earlier appropriate therapy, reduced unnecessary broad-spectrum antibiotic use, shorter length of stay, improved laboratory productivity, and alignment with sepsis quality programs. Companies should invest in regional evidence generation, reimbursement strategy, cybersecurity for connected diagnostics, user training, and partnerships with hospitals that can validate real-world performance across diverse patient populations. Leaders should also adapt product configurations for resource-variable settings, including simplified workflows, robust sample handling, and clear clinical interpretation.

Research Methodology

This executive summary is developed using a structured secondary-research methodology grounded in verified public health, regulatory, clinical, and market-relevant sources. Key inputs include WHO and CDC sepsis burden data, peer-reviewed literature on sepsis biomarkers and molecular diagnostics, antimicrobial resistance policy documents, regulatory guidance for in vitro diagnostics and software as a medical device, and publicly available hospital quality initiatives.

Insights are synthesized through triangulation across disease burden, technology adoption, laboratory workflow, regional healthcare infrastructure, regulatory maturity, and commercial readiness. Emphasis is placed on evidence-backed interpretation rather than speculative claims, with attention to diagnostic utility, implementation constraints, and the practical requirements of clinicians, microbiologists, payers, and health system decision-makers. The analysis avoids market sizing, share estimates, and forecasts, focusing instead on verified adoption drivers and operational implications.

Conclusion

Sepsis diagnostics are entering a more integrated era defined by speed, accuracy, stewardship, and clinical workflow alignment. While blood culture remains foundational, the field is increasingly shaped by molecular diagnostics, host-response biomarkers, automated microbiology, lactate and procalcitonin testing, antimicrobial susceptibility workflows, and AI-enabled decision support that can help identify high-risk patients earlier.

The next phase of adoption will favor organizations that prove clinical value in real-world settings and adapt solutions to regional healthcare realities. As sepsis continues to impose a major global mortality and economic burden, reliable diagnostics that accelerate evidence-based treatment will remain essential to patient outcomes, hospital performance, antimicrobial resistance control, and health system resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Sepsis Diagnostic Market, by Product Type

  • 7.1. Instruments
    • 7.1.1. Analyzers
    • 7.1.2. Point-Of-Care Devices
  • 7.2. Reagents & Kits
    • 7.2.1. Biomarker Kits
    • 7.2.2. Culture Media
  • 7.3. Software & Services
    • 7.3.1. Consulting Services
    • 7.3.2. Data Management Software

8. Sepsis Diagnostic Market, by Technology

  • 8.1. ELISA
    • 8.1.1. Competitive ELISA
    • 8.1.2. Sandwich ELISA
  • 8.2. Flow Cytometry
    • 8.2.1. Conventional Flow Cytometry
    • 8.2.2. Imaging Flow Cytometry
  • 8.3. NGS
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Genome Sequencing
  • 8.4. PCR
    • 8.4.1. Multiplex PCR
    • 8.4.2. Real-Time PCR

9. Sepsis Diagnostic Market, by End User

  • 9.1. Ambulatory Care Centers
    • 9.1.1. Clinics
    • 9.1.2. Outpatient Centers
  • 9.2. Diagnostic Laboratories
    • 9.2.1. Clinical Laboratories
    • 9.2.2. Reference Laboratories
  • 9.3. Hospitals
    • 9.3.1. General Hospitals
    • 9.3.2. Tertiary Care Hospitals

10. Sepsis Diagnostic Market, by Distribution Channel

  • 10.1. Direct
  • 10.2. Indirect
    • 10.2.1. Distributors
    • 10.2.2. E-Commerce

11. Sepsis Diagnostic Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Sepsis Diagnostic Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Sepsis Diagnostic Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Alifax S.r.l.
  • 15.3. Beckman Coulter, Inc.
  • 15.4. Becton, Dickinson and Company
  • 15.5. bioMerieux SA
  • 15.6. Boditech Med Inc.
  • 15.7. Bruker Corporation
  • 15.8. CytoSorbents Corporation
  • 15.9. DiaSorin S.p.A.
  • 15.10. EKF Diagnostics
  • 15.11. F. Hoffmann-La Roche AG
  • 15.12. Immunexpress Inc.
  • 15.13. Koninklijke Philips N.V.
  • 15.14. McKesson Corporation
  • 15.15. Merck KGaA
  • 15.16. Molzym GmbH & Co. KG
  • 15.17. Nanomix Inc.
  • 15.18. Oracle Corporation
  • 15.19. QIAGEN N.V.
  • 15.20. Response Biomedical Corporation
  • 15.21. Seegene Inc.
  • 15.22. Siemens Healthineers
  • 15.23. T2 Biosystems
  • 15.24. Thermo Fisher Scientific, Inc.
  • 15.25. Wolters Kluwer N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SEPSIS DIAGNOSTIC MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL SEPSIS DIAGNOSTIC MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL SEPSIS DIAGNOSTIC MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL SEPSIS DIAGNOSTIC MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL SEPSIS DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL SEPSIS DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT-OF-CARE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT-OF-CARE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT-OF-CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOMARKER KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOMARKER KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOMARKER KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CULTURE MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CULTURE MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONSULTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONSULTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONSULTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPETITIVE ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPETITIVE ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPETITIVE ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SANDWICH ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SANDWICH ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SANDWICH ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONVENTIONAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONVENTIONAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONVENTIONAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMAGING FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMAGING FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMAGING FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIPLEX PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MULTIPLEX PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIPLEX PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL REAL-TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL REAL-TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL REAL-TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OUTPATIENT CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OUTPATIENT CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OUTPATIENT CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CLINICAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CLINICAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CLINICAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIRECT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIRECT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIRECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INDIRECT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INDIRECT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INDIRECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DISTRIBUTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DISTRIBUTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DISTRIBUTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL E-COMMERCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL E-COMMERCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL E-COMMERCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 222. GCC SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 229. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 232. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 235. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GCC SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 270. G7 SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 277. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 280. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 283. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. G7 SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 286. NATO SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 293. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 294. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 296. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 299. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 300. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. NATO SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 302. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 323. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 338. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 339. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 340. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 341. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 342. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 343. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 344. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 345. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 346. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 347. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 348. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 349. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 350. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 351. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 352. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 353. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 354. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 355. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 356. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 357. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 358. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 359. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 360. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 361. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 362. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 363. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 364. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 365. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 366. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY INDIRECT, 2018-2032 (USD MILLION)
  • TABLE 367. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 368. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 369. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 370. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 371. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 372. UNITED KINGDOM SEPSIS DIAGNO